Bank of America
MREO

Bank of America’s Mereo BioPharma MREO Stock Holding History

Bank of America’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7M Buy
8,195,287
+8,169,795
+32,048% +$3.51M ﹤0.01% 3906
2025
Q4 		$10.6K Sell
25,492
-413,130
-94% -$786K ﹤0.01% 6154
2025
Q3 		$904K Sell
438,622
-39
-0% -$72 ﹤0.01% 5398
2025
Q2 		$1.19M Sell
438,661
-9
-0% -$22 ﹤0.01% 5179
2025
Q1 		$987K Buy
438,670
+436,350
+18,808% +$1.23M ﹤0.01% 5226
2024
Q4 		$8.12K Sell
2,320
-215,237
-99% -$846K ﹤0.01% 7019
2024
Q3 		$894K Buy
217,557
+133,539
+159% +$552K ﹤0.01% 5122
2024
Q2 		$302K Buy
84,018
+5,300
+7% +$17.2K ﹤0.01% 5656
2024
Q1 		$260K Buy
78,718
+78,442
+28,421% +$266K ﹤0.01% 5746
2023
Q4 		$638 Sell
276
-8,942
-97% -$17.1K ﹤0.01% 7254
2023
Q3 		$11.9K Buy
9,218
+9,217
+921,700% +$12.2K ﹤0.01% 6820
2023
Q2 		$1 Sell
1
-21,182
-100% -$24.6K ﹤0.01% 7658
2023
Q1 		$15K Sell
21,183
-46,347
-69% -$41.7K ﹤0.01% 6837
2022
Q4 		$50.6K Buy
67,530
+34,805
+106% +$28.6K ﹤0.01% 6476
2022
Q3 		$28K Sell
32,725
-34,153
-51% -$41.8K ﹤0.01% 6906
2022
Q2 		$74K Sell
66,878
-132,771
-67% -$103K ﹤0.01% 6633
2022
Q1 		$223K Buy
199,649
+128,367
+180% +$166K ﹤0.01% 6402
2021
Q4 		$114K Buy
71,282
+30,442
+75% +$60.9K ﹤0.01% 6825
2021
Q3 		$99K Sell
40,840
-13,593
-25% -$36K ﹤0.01% 6732
2021
Q2 		$173K Buy
54,433
+52,778
+3,189% +$177K ﹤0.01% 6190
2021
Q1 		$6K Hold
1,655
– – ﹤0.01% 7097
2020
Q4 		$6K Hold
1,655
– – ﹤0.01% 6803
2020
Q3 		$5K Hold
1,655
– – ﹤0.01% 6587
2020
Q2 		$5K Hold
1,655
– – ﹤0.01% 6562
2020
Q1 		$1K Hold
1,655
– – ﹤0.01% 6720
2019
Q4 		$6K Sell
1,655
-10,449
-86% -$26.7K ﹤0.01% 6734
2019
Q3 		$36K Hold
12,104
– – ﹤0.01% 6429
2019
Q2 		$31K Buy
+12,104
New +$52.9K ﹤0.01% 6464

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America's MREO Position: Q1 2026 in Review

Bank of America increased its Mereo BioPharma (MREO) stake by 32,048% in Q1 2026, buying an estimated $3.51M and bringing the position to 8,195,287 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3906.

Bank of America first reported a position in MREO in Q2 2019 and has held it in 28 quarters since. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Bank of America held 8,195,287 shares of Mereo BioPharma worth $2.7M as of Q1 2026.
  • Bank of America bought 8,169,795 Mereo BioPharma shares in Q1 2026, an estimated $3.51M.
  • Mereo BioPharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3906 holding.
  • Bank of America first reported a position in Mereo BioPharma in Q2 2019 and has held it in 28 quarters since.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.